A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

BACKGROUND: Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a humanized RSV monoclonal antibody (MAb). In preclinical in vitro and in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández, Pilar, Trenholme, Adrian, Abarca, Katia, Griffin, M Pamela, Hultquist, Micki, Harris, Brian, Losonsky, Genevieve A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898783/
https://www.ncbi.nlm.nih.gov/pubmed/20525274
http://dx.doi.org/10.1186/1471-2431-10-38

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898783/
https://www.ncbi.nlm.nih.gov/pubmed/20525274
http://dx.doi.org/10.1186/1471-2431-10-38

Ejemplares similares